PURPOSE: To investigate the feasibility of conducting a randomised controlled trial in @entity1 undergoing pars plana vitrectomy surgery following @entity130 ( @entity130 ). Additionally, to investigate the treatment effect and @entity137 of intensive anti-inflammatory agents. METHODS: A 2-year, pilot, single-centre prospective, @entity1 and surgeon-masked randomised controlled trial (RCT). Forty @entity1 requiring vitrectomy surgery following @entity130 were randomised to either standard (control) or study treatment (adjuncts) in a 1:1 allocation ratio. Perioperatively, the adjunct group received intravitreal and subtenons @entity2995 , oral @entity8726 and guttae @entity12356 1%. The control group received standard care. Primary outcome was anatomical success at 6   months. Secondary outcomes included final visual acuity, occurrence of proliferative @entity1715 , intraocular pressure rise, number of operations and recruitment rate. RESULTS: 40 @entity1 were recruited within 21   months. Primary outcome assessment showed similar results in anatomical success with 50% (10/20) in the adjunct group compared with 47% (9/19) in the standard group (OR 1.11, 95% CI 0.316 to 3.904). Visual outcomes were better in the adjunct group with a final median visual acuity of 31 Early Treatment @entity6 Study (ETDRS) letters compared with 25 ETDRS letters in the standard group. A higher proportion of @entity1 gained 10, 20 and 30 ETDRS letters in the adjunct group (80%, 65% and 50%, respectively) compared with the standard group (52.6%, 52.6% and 42.1%). Fewer adjunct @entity1 (15%, n=3) had poor visual outcomes (Zero ETDRS letters) compared with 42.1%, (n=8). CONCLUSIONS: An RCT in this population is deliverable and estimated recruitment rates are realistic. Results and @entity1 discussions determined that the definitive study should have vision as a primary outcome. This pilot study is supportive of there being a positive treatment effect of intensive anti-inflammatory agents in @entity130 . TRIAL REGISTRATION NUMBER: European Clinical Trials Database 2007-005138-35; Results.

Triamcinolone during pars plana vitrectomy for XXXX : a pilot randomised controlled clinical trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'participant', 'patient'] @entity2995 :: ('MESH:D014222', 'Chemical') :: ['triamcinolone acetonide'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1715 :: ('MESH:D018630', 'Disease') :: ['vitreoretinopathy'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic Retinopathy'] @entity12356 :: ('MESH:C009935', 'Chemical') :: ['prednisolone acetate'] @entity8726 :: ('MESH:D005480', 'Chemical') :: ['flurbiprofen'] @entity130 :: ('MESH:D014947', 'Disease') :: ['open globe trauma', 'OGT']
@entity130 :: (MESH:D014947,Disease) :: ['open globe trauma']
